Moore_Nathan

Nathan J. Moore

Moore_Nathan

Nathan J. Moore

Partner

Denver + 1 720 598 3462 New York + 1 212 295 6386

Nathan Moore has developed a distinguished practice over the years by successfully guiding a diverse roster of corporate and lending clients through all aspects of their debt, royalty and acquisition financing transactions. Mr. Moore has a broad range of experience representing private equity funds, financial institutions, and public and private companies active across a diverse range of industries, with a particular focus in the life sciences, technology and financial services sectors. He is also active with emerging growth companies throughout their development cycle (learn more about Mr. Moore’s emerging growth company practice on WilmerHaleLaunch.com). With his invaluable practice experience and focus on business-oriented solutions, Mr. Moore provides exceptional service and is a trusted business advisor for clients on all their debt, royalty and acquisition financing challenges.

Mr. Moore’s experience includes structuring, negotiating and closing royalty purchase and other specialty finance transactions, and a wide array of secured and unsecured debt financing transactions, including leveraged buyouts, syndicated investment grade facilities, recapitalizations, private placements of debt securities, asset-based financings, venture debt, and mezzanine and subordinated debt financings. Mr. Moore is an active member of the Colorado legal community, devoting significant time and resources to local non-profits.  He was recognized by the Colorado Lawyers Committee for his role in creating and supporting the Colorado COVID Legal Relief Program, which provided pro bono legal assistance to more than 250 small businesses affected by the pandemic.

Experience

  • Debt Financings

    • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, in its $5 billion unsecured five-year revolving credit facility
    • Revvity, Inc. (NYSE: RVTY), a leading provider of health science solutions, technologies, expertise and services, in its $1.5 billion unsecured five-year revolving credit facility
    • Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, in connection with a new $100 million first lien senior secured term loan facility and a related amendment to its royalty financing agreement with HealthCare Royalty
    • Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company that develops life-changing therapies, in connection with a non-dilutive, senior secured credit facility with Sixth Street, a leading global investment firm, of up to $475 million, and a receivables purchase facility with Citibank, N.A. of up to $100 million
    • Wilmington Savings Fund Society, FSB as administrative and collateral agent in an approximately $553.5 million senior secured exit financing with Pennsylvania Real Estate Investment Trust as borrower following its emergence from Chapter 11 bankruptcy
    • Medtronic plc (NYSE: MDT), global producer of medical devices and therapies, in its JPY300 billion ($1.98 billion) term loan
    • MicroStrategy Incorporated (Nasdaq: MSTR), a pioneer in AI-powered business intelligence, in a $205 million credit facility for its subsidiary, MacroStrategy, which was secured entirely by bitcoin

  • Royalty Financings

    • PTC Therapeutics (Nasdaq: PTCT), a global biopharmaceutical company, in connection with its agreement with Royalty Pharma plc to monetize PTC’s remaining interests in its Evrysdi royalty stream for up to $1.5 billion
    • Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, in connection with the sale of rights to its 15% royalty on potential US net sales of Servier’s Vorasidenib to Royalty Pharma for $905 million 
    • Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, in connection with the announced sale of certain future license fees and other payments owed to Editas under its Cas9 license agreement with Vertex Pharmaceuticals Incorporated to a subsidiary of DRI Healthcare Trust for an upfront cash payment of $57 million

  • Acquisition Financings

    • Navient Corporation (Nasdaq: NAVI), a provider of technology-enabled education finance and business processing solutions, in connection with the financing elements of its agreement to sell Xtend Healthcare, its healthcare revenue cycle management business, to CorroHealth, a leading health technology company, for $365 million in cash consideration
    • Spectris plc, a supplier of high-tech precision instruments, in the financing elements of its acquisition of Micromeritics Instrument Corporation, a world leader in analytical instrumentation, for consideration of $630 million plus deferred consideration
    • The Nordstrom family in connection with the financing elements of its definitive agreement to acquire, along with Mexican retailer El Puerto de Liverpool, all of Nordstrom, Inc.’s outstanding shares in an all-cash transaction valued at approximately $6.25 billion
    • TMX Group, a company that operates global markets and develops digital communities and analytic solutions, in the financing elements of its agreement to acquire the remaining approximately 78% of the common units of VettaFi, a leading US-based company specializing in indexing, digital distribution, analytics and thought leadership
    • Lookout, Inc., an endpoint-to-cloud security company built for the intersection of enterprise and personal data, in connection with the financing elements of its agreement to sell its consumer mobile security business to F-Secure, a global provider of consumer security products and services
    • Blue Apron Holdings, Inc. in the financing elements of its acquisition by Wonder Group, Inc., a company founded by entrepreneur Marc Lore, for $103 million 
    • Navient Corporation (Nasdaq: NAVI), a provider of technology-enabled education finance and business processing solutions, in connection with the financing elements of the sale of its government services business to an affiliate of Gallant Capital Partners, LLC, a Los Angeles-based investment firm

Recognition

  • Recognized by Chambers USA Guide for his Banking & Finance practice. Clients describe Mr. Moore as "very knowledgeable and experienced...he is amazing to work with, he goes above and beyond to help us out.
  • Received “Pandemic Heroes” award from the Colorado Lawyers Committee, recognizing significant efforts in creating and supporting the Colorado COVID Legal Relief Program, which has provided pro bono legal assistance to more than 250 small businesses affected by the pandemic.

Insights & News

View all of Nathan's insights & news

Credentials

  • Education

    • JD, University of Michigan Law School, 2012

      cum laude

    • BA, English, Truman State University, 2005

      cum laude

  • Admissions

    • Colorado

    • Illinois

    • New York

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel